Cargando…
Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab
IMPORTANCE: Prurigo nodularis (PN) is a debilitating skin disease characterized by intense pruritus and hyperkeratotic skin nodules. Nemolizumab, a monoclonal antibody targeting interleukin 31 receptor α, is a promising novel therapy for the treatment of moderate to severe PN. The biological mechani...
Autores principales: | Deng, Junwen, Liao, Viviane, Parthasarathy, Varsha, Cornman, Hannah L., Kambala, Anusha, Kwatra, Madan M., Ständer, Sonja, Piketty, Christophe, Chaskar, Prasad, Krishnaswamy, Jayendra Kumar, Julia, Valerie, Kwatra, Shawn G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413221/ https://www.ncbi.nlm.nih.gov/pubmed/37556125 http://dx.doi.org/10.1001/jamadermatol.2023.2609 |
Ejemplares similares
-
Clinical utility of peripheral blood laboratory testing in the diagnostic workup of prurigo nodularis: A multicenter cohort study
por: Cornman, Hannah L., et al.
Publicado: (2023) -
Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis
por: Deng, Junwen, et al.
Publicado: (2022) -
Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis
por: Rajeh, Ahmad, et al.
Publicado: (2023) -
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
por: Ständer, S., et al.
Publicado: (2022) -
Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularis
por: Patel, Jay R., et al.
Publicado: (2023)